Flora Pirozzi

Flora Pirozzi

Auto-generated profile, based on publicly available information

Flora Pirozzi

Department of Translational Medical Sciences, University of Naples Federico II, Napoli, Italy

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2016 in Experimental Gerontology
Verified
Journal Article
Closed access
FCFrancesco Curcio
Francesco Curcio
GFGaetana Ferro
Gaetana Ferro
CBClaudia Basile
Claudia Basile
ILIlaria Liguori
Ilaria Liguori
PPPaolo Parrella
Paolo Parrella
PAPasquale Abete
Pasquale Abete

14 August 2018 in Circulation
Verified
Journal Article
Closed access
PDF file
MLMingchuan Li
Mingchuan Li
VSValentina Sala
Valentina Sala
MSMaria Chiara De Santis
Maria Chiara De Santis
JCJames Cimino
James Cimino
Paola CappelloPaola Cappello
Paola Cappello
AGAlessandra Ghigo
Alessandra Ghigo
Background: Anthracyclines, such as doxorubicin (DOX), are potent anticancer agents for the treatment of solid tumors and hematologic malignancies. However, their clinical use is hampered by cardiotoxicity. This study sought to investigate the role of phosphoinositide 3-kinase γ (PI3Kγ) in DOX-induced cardiotoxicity and the potential cardioprotective and anticancer effects of PI3Kγ inhibition. Methods: Mice expressing a kinase-inactive PI3Kγ or receiving PI3Kγ-selective inhibitors were subjected to chronic DOX treatment. Cardiac function was analyzed by echocardiography, and DOX-mediated signaling was assessed in whole hearts or isolated cardiomyocytes. The dual cardioprotective and antitumor action of PI3Kγ inhibition was assessed in mouse mammary tumor models. Results: PI3Kγ kinase-dead mice showed preserved cardiac function after chronic low-dose DOX treatment and were protected against DOX-induced cardiotoxicity. The beneficial effects of PI3Kγ inhibition were causally linked to enhanced autophagic disposal of DOX-damaged mitochondria. Consistently, either pharmacological or genetic blockade of autophagy in vivo abrogated the resistance of PI3Kγ kinase-dead mice to DOX cardiotoxicity. Mechanistically, PI3Kγ was triggered in DOX-treated hearts, downstream of Toll-like receptor 9, by the mitochondrial DNA released by injured organelles and contained in autolysosomes. This autolysosomal PI3Kγ/Akt/mTOR/Ulk1 signaling provided maladaptive feedback inhibition of autophagy. PI3Kγ blockade in models of mammary gland tumors prevented DOX-induced cardiac dysfunction and concomitantly synergized with the antitumor action of DOX by unleashing anticancer immunity. Conclusions: Blockade of PI3Kγ may provide a dual therapeutic advantage in cancer therapy by simultaneously preventing anthracyclines cardiotoxicity and reducing tumor growth.

1 October 2011 in The American Journal of Cardiology
Verified
Journal Article
Closed access
Mario PetrettaMario Petretta
Mario Petretta
FPFlora Pirozzi
Flora Pirozzi
LSLaura Sasso
Laura Sasso
APAntonella Paglia
Antonella Paglia
DBDomenico Bonaduce
Domenico Bonaduce

1 June 2016 in Journal of Cardiac Failure
Verified
Journal Article
Closed access
VMValentina Mercurio
Valentina Mercurio
FPFlora Pirozzi
Flora Pirozzi
Edoardo LazzariniEdoardo Lazzarini
Edoardo Lazzarini
GMGiancarlo Marone
Giancarlo Marone
PRPaola Rizzo
Paola Rizzo
PAPietro Ameri
Pietro Ameri

2 December 2020 in Current Oncology Reports
Verified
Journal Article
Open access
PDF file
Alessandra CuomoAlessandra Cuomo
Alessandra Cuomo
FPFlora Pirozzi
Flora Pirozzi
UAUmberto Attanasio
Umberto Attanasio
RFRiccardo Franco
Riccardo Franco
FEFrancesco Elia
Francesco Elia
VMValentina Mercurio
Valentina Mercurio
Purpose of Review: Along with population aging, the incidence of both heart failure (HF) and cancer is increasing. However, little is known about new-onset cancer in HF patients. This review aims at showing recent discoveries concerning this subset of patients.Recent Findings: Not only cancer and HF share similar risk factors but also HF itself can stimulate cancer development. Some cytokines produced by the failing heart induce mild inflammation promoting carcinogenesis, as it has been recently suggested by an experimental model of HF in mice.Summary: The incidence of new-onset cancer is higher in HF patients compared to the general population, and it significantly worsens their prognosis. Moreover, the management of HF patients developing new-onset cancer is challenging, especially due to the limited therapeutic options for patients affected by both cancer and HF and the higher risk of cardiotoxicity from anticancer drugs.

26 July 2019 in The Journal of Physiology
Verified
Journal Article
Closed access
PDF file
MBMara Brancaccio
Mara Brancaccio
FPFlora Pirozzi
Flora Pirozzi
EHEmilio Hirsch
Emilio Hirsch
AGAlessandra Ghigo
Alessandra Ghigo